Friday, August 31, 2007

Market Comments Submitted by Nick at Ambitions as a Stock Trader

Submitted by My Ambitions as a Trader and Investor

New Buys: BW


Reasons behind trade: BW seems to be coming off of a double bottom formation. It has shown consistant support at 35 where it had begun its positive reversal. The stock has recently climbed above its 200 day MA and has shown support above this level.

BW


My Ambitions as a Trader and Investor is not a registered investment advisor. Please read the complete Small Cap Stocks Blog Disclaimer

Visit 1800blogger to see all of our industry leading blogs

Labels: , ,

Market Scan for Small Cap Stocks on August 30, 2007

Submitted by Ducimus Plinius

Market Scan for small cap stocks
at the close of the markets on August 30, 2007


The table below identifies the stocks returned on my scan of the US markets for small capitalizations stocks likely to display the characteristics of stocks entering Phase II, as described by Stan Weinstein.


Click Image to Enlarge



Ducimus Pliniusis not a registered investment advisor. Please read the complete Small Cap Stocks Blog Disclaimer

Visit 1800blogger to see all of our industry leading blogs

Labels: , , , , , , , , ,

Knobias ClipReport (8-31-2007)

Submitted from Knobias ClipReport

While many feel that Hillary doesn’t have a chance to be the next president, the Democrats could still pull out the election especially considering the continued predicaments that Republicans have put themselves in with Larry Craig’s ordeal, the Gonzalez resignation, and David Vitter’s scandal.

The hits keep coming for the party which could undoubtedly cause the president’s party to see a change of hands. With the many initiatives that have recently been repealed by the Republican president and the scandals the party is currently facing, it could be time to revisit some of the sectors that saw increased action on the vetoed legislation. Stem cell stocks could easily become a hot sector again with a Democratic President as could alternate energy names. Even though solar has been very hot this past summer, the entire sector could see a huge increase in attention with a Democrat at the helm.

One name in particular is Akeena Solar, Inc. (AKNS). The Company is a designer, installer, marketer, and seller of solar power systems for residential and small commercial customers.

Solar energy systems are expensive, but generous incentives make them affordable. Fortunately, there are a wide range of federal, state and local programs that substantially offset these costs in the form of tax credits, rebates, grants, loans, leasing and direct equipment sales.

Business customers enjoy substantial benefits in return for their solar purchases. The combination of state solar energy tax credits, the Federal 10% investment tax credit, and accelerated five-year depreciation means that solar energy systems generate substantial positive cash flow, particularly in the first five years of operation.

The Company reported second quarter earnings in early August. Net sales for the second quarter of 2007 were $7.5 million, compared to $2.8 million of net sales in the second quarter of 2006. Gross profit for the second quarter 2007 was $1.8 million, or 24 percent of sales, compared to $715,000, or 25 percent of sales in the second quarter of 2006. Net loss for the second quarter of 2007 was $1.9 million or $0.10 per share, compared to net loss of $248,000 or $0.03 per share in the second quarter of 2006. For 2007 management reiterated its guidance for revenue growth of approximately 135 percent over 2006 revenue of $13.4 million.

With the addition of 2 new locations, the California footprint is building while the Company also has locations in New York, New Jersey, and also services Connecticut.

The California market has seen huge increases in the demand for the products which the Company has attempted to service with the added locations. The traction these new locations have gained could be evident with the Company’s third quarter earnings release which is expected to be reported in mid November.

In the meantime, the Company could see increased attention following their presentation at Kaufman Brothers Investor Conference on September 5th. With the Democrats eyeing the top seat in the government and their lean towards alternate energy prospects, the sector deserves increased attention with the republican scandals currently residing atop news headlines. With any type of increased subsidizing or footprint, the sector is one to follow. Investors would be wise to watch.


Visit 1800blogger to see all of our industry leading blogs

Labels: ,

Thursday, August 30, 2007

Market Comments Submitted by Nick at Ambitions as a Stock Trader

Submitted by My Ambitions as a Trader and Investor

Trying to Sit Tight...

Sitting tight and not trading is difficult to do. Yet, in our current market enviornment, it is probably the safest and smartest actions that an active trader can perform. I've been tempted to add some of my current holdings and I've been tempted to buy several interesting stocks. Still, I have to constantly remind myself of the markets volatile and trendless action. Of course, I will still be on the look out for any new possibilities for both long and short trades....

My Ambitions as a Trader and Investor is not a registered investment advisor. Please read the complete Small Cap Stocks Blog Disclaimer


Visit 1800blogger to see all of our industry leading blogs

Labels: ,

Market Comments Submitted by Nick at Ambitions as a Stock Trader

Submitted by My Ambitions as a Trader and Investor

Laterally Trending Market...

The current market conditions that we have been experiencing are quite possibly the most difficult to trade in. Laterally (or sideways) trending markets do not provide rewarding opportunities for both longs or shorts. Instead, they are filled with traps that can easily drain ones account. Trying to predict what the market will do next is not a game that I would like to play. It is a losing game at best. But still, by examining the chart a few days ago, I posted that if the DJIA can break above or close onto or above 13,200 that it would head higher and that if it closed below that point, it would have headed lower. Well it did close above the 13,200 point and lo and behold, it jumped up quite considerably. In order for the DJIA to break out above its 50 day MA, the 13,200 point needs to act as support (much like a spring board). Again, violating the 13,200 point can send the market further down again to retest the lows. Unless we trade sideways the whole time, next week should be rather interesting as far as the future direction of the market is concerned.

My Ambitions as a Trader and Investor is not a registered investment advisor. Please read the complete Small Cap Stocks Blog Disclaimer


Visit 1800blogger to see all of our industry leading blogs

Labels: ,

Market Scan for Small Cap Stocks on August 29, 2007

Submitted by Ducimus Plinius

Market Scan for small cap stocks
at the close of the markets on August 29, 2007


The table below identifies the stocks returned on my scan of the US markets for small capitalizations stocks likely to display the characteristics of stocks entering Phase II, as described by Stan Weinstein.


Click Image to Enlarge



Ducimus Pliniusis not a registered investment advisor. Please read the complete Small Cap Stocks Blog Disclaimer

Visit 1800blogger to see all of our industry leading blogs

Labels: , , , , , , , , ,

Knobias ClipReport (8-30-2007)

Submitted from Knobias ClipReport

Silverstar Holdings Ltd. (SSTR) reported preliminary fourth quarter numbers during Wednesday’s session that had many take notice because of the large increases year over year.

The Company reported expectations of revenues for the fourth quarter to range between $11.5 million to $11.9 million, as compared to $467,000 in the fourth quarter of 2006. EBITDA is estimated to range between $4.0 million and $4.4 million for the fourth quarter, or between $0.40 and $0.44 per diluted share, as compared to a negative EBITDA of $1.8 million or ($0.19) per diluted share a year ago. Operating income is expected between $1.6 million and $1.9 million, or $0.15 to $0.18 per diluted share, as compared to a year-ago fourth quarter loss from continuing operations of $2.4 million or ($0.25) per share. The calculations were based on an estimated 10.4 million diluted shares.

Following the announcement, SSTR gained 42.5% on over 3.65 million shares traded. The Company is an international publisher and developer of interactive entertainment software. It currently owns Empire Interactive, PLC and Strategy First, Inc. Empire Interactive (www.empireinteractive.com) is a leading developer and publisher of interactive entertainment software games, including Starsky & Hutch, Big Mutha Truckers, Ford Racing and FlatOut. Empire's products are delivered on both console and PC platforms. Strategy First (www.strategyfirst.com) is a developer and worldwide publisher of entertainment software for the PC.

Contributing to the expected increased results was the recent acquisition of Empire Interactive consummated at the end of 2006.

The Company noted that their business model is successful when they release high profile titles alongside their other releases. They noted that games like Jackass, Hello Kitty, Pipe Dreams, Disciples III, and Ford Off Road Racing performed well and caused other names in their portfolio to receive attention as well.

The European market could also make an impact as the Company plans to release their back catalog of names to the continent over the next 12 months.

The Company has released preliminary reports before. In April, they announced revenue expectations of $4.3 million to $4.5 million for the third quarter. Incorporated into the release was a fourth quarter expectation of revenue between $10.5 million and $12.5 million. Following the preliminary results announcement, shares gained some 26.7% on 328 thousand shares in volume.

Shares held that gain until a private placement announcement in July caused them to fall until Wednesday’s news. While the entire placement amount wasn’t fully implemented, warrants were issued that allowed purchase of 4.34 million shares in the $2.10 range.

With the investors of the placement (CEO Clive Kabatznik and Michael Levy, Chairman were noted as two of the private parties) in the money at current levels and the Company possibly needing a cash injection to fund international sales efforts, another S-3 filing could be on the horizon.

In any event, with the extremely picky gaming consumers as their target audience and a cash position that has the possibility of being increased through additional dilutive measures, investors might be wise to watch.


Visit 1800blogger to see all of our industry leading blogs

Labels: , ,

Wednesday, August 29, 2007

Market Scan for Small Cap Stocks on August 28, 2007


Submitted by Ducimus Plinius

Market Scan for small cap stocks
at the close of the markets on August 28, 2007


The table below identifies the stocks returned on my scan of the US markets for small capitalizations stocks likely to display the characteristics of stocks entering Phase II, as described by Stan Weinstein.


Click Image to Enlarge



Ducimus Pliniusis not a registered investment advisor. Please read the complete Small Cap Stocks Blog Disclaimer

Visit 1800blogger to see all of our industry leading blogs

Labels: , , , , , , , , , ,

Knobias ClipReport (8-29-2007)

Submitted from Knobias ClipReport

Scivanta Medical Corporation (SCVM) has entered into a development agreement with Sparton Medical Systems, a business group of Sparton Electronics Florida, Inc. which is a wholly-owned subsidiary of Sparton Corporation (SPA). Sparton will provide engineering and development support for the hardware component of the Hickey Cardiac Monitoring System (HCMS).

Sparton will plan and develop the design control documents; concept development, including mechanical, electrical and software design; completion of a detailed design and an engineering model; assembly of proto-type models and preliminary design verification testing; the production of "pilot" devices using formal drawings and validated processes; and design verification testing on the "pilot" units. The estimated cost for Scivanta under the development agreement are estimated to be up to $1,650,000 for services and materials.

President and CEO of Scivanta, David LaVance, told Knobias on Tuesday, "Sparton is an experienced engineering, designing and manufacturing firm that has a specialty in medical devices that operate similarly to the Hickey Cardiac Monitoring System. They have long worked in the fields of cardiac devices and other systems requiring automated pumps and monitors, as well as integrated electronics. Their facilities are superb, and they have a team of engineers and technicians dedicated to medical device engineering and manufacturing."

The Hickey Cardiac Monitoring System is a minimally-invasive two-balloon esophageal catheter system used to monitor cardiac performance. It is designed to be used outside of an intensive care setting.

Mr. LaVance noted, "The catheter component of the HCMS is being developed by Ethox International, Inc., while the software for the product is being developed by Applied Sciences Group, Inc. With Sparton now signed on to develop the hardware for the system, the development team necessary to bring the HCMS to the market is now intact. Given the established safety of esophageal balloon catheters, the Hickey monitor is currently entering a 510(k) expedited review with the FDA. Sales could be launched in about a year if trials demonstrate its safety and effectiveness to the FDA. We have already secured the funds necessary to design and manufacture the HCMS through the clinical trails stage."

"The gold standard for current cardiac monitoring technologies is the Swan-Ganz catheter, an instrument that is inserted through a patient's femoral artery and snaked into the heart. Aside from the obvious benefit of eliminating the need for a surgical procedure, the HCMS offers a number of other improvements over today’s standard for cardiac monitoring that include a minimally invasive esophageal route that reduces infection and other systemic adverse events; rapid insertion and positioning by non-physician personnel; performs phonocardiogram and monitors audible heart sounds unaffected by surrounding noise; includes integrated ECG and blood pressure measurement; disposable non-metal components that do not interfere with magnetic resonance imaging; instantaneous analysis and display of cardiac performance; and estimated maximum total cost of approximately $600, compared with $1800 for the Swan-Ganz catheter," he explained.

Mr. LaVance commented on the potential market impact of the HCMS, "The market for standard cardiac monitoring is more than 1 million procedures a year, a figure that non-invasive technology could greatly expand because of its ability to be performed outside of intensive care units. In the year 2000, direct and indirect costs of cardiovascular disease was $325 billion. The Hemodynamic monitoring market was estimated at $500 million in 2006, with a a 30% compound annual growth rate projected for noninvasive hemodynamic monitors."

According to a University of Buffalo research study, "The Hickey Cardiac Monitoring System has tremendous market potential. The system will generate sales from the consumer catheter component and capital equipment. The capabilities of make it well suited for other applications as well. Anesthesiologists may find the HCMS a useful tool when monitoring patients undergoing treatment for aneurysms, bowel obstruction, ruptured ectopic pregnancies, trauma surgery and burn management, or other heavy fluid-loss surgery that requires close monitoring of fluid balance and cardiac performance."

Mr. LaVance concluded, "Currently we are focusing our efforts toward the development of the HCMS. We expect to continue to review the acquisition of other medical technologies and products that are sold, or capable of being sold, in a specialty or niche market."
Visit 1800blogger to see all of our industry leading blogs

Labels: , ,

Tuesday, August 28, 2007

Market Comments

Submitted by My Ambitions as a Trader and Investor

Lazy Monday

There is only one word that can accurately describe todays market action. And that single word is.....BORING! Maybe it was the lack of volume or interesting trading action or something else. Regardless, todays tepid action is a wonderful reminder that the traders and institutional investors are still in summer vacation mode. I couldn't find that many interesting trades. Previous candidates are still doing quite fine such as TOD, VII, SHEN, SLI, etc. I've built up my watchlist a bit over the weekend but I didn't have much time to go through it. After today, it will be much easier to weed out the bad apples on my list. Despite the markets slightly negative bias, the low volume makes this more of a pullback, which is to be expected following last weeks bullish action. For now, enjoy the last few weeks of vacation, go to the beach and just have fun because in a few weeks the warm, lazy days of summer will fade away.


My Ambitions as a Trader and Investor is not a registered investment advisor. Please read the complete Small Cap Stocks Blog Disclaimer

Visit 1800blogger to see all of our industry leading blogs

Labels: ,

Market Scan for Small Cap Stocks on August 27, 2007

Submitted by Ducimus Plinius

Market Scan for small cap stocks
at the close of the markets on August 27, 2007


The table below identifies the stocks returned on my scan of the US markets for small capitalizations stocks likely to display the characteristics of stocks entering Phase II, as described by Stan Weinstein.



Click Image to Enlarge



Ducimus Pliniusis not a registered investment advisor. Please read the complete Small Cap Stocks Blog Disclaimer

Visit 1800blogger to see all of our industry leading blogs

Labels: , , , , , , , , ,

Knobias ClipReport (8-28-2007)

Submitted from Knobias ClipReport

Monday’s session began with news that the housing supply hit a 16 year high signaling that speculators were still stuck and the bubble may have a ways to go before finishing its course. Internationally though, Hong Kong’s benchmark index, the Hang Seng, closed at its all time high of 23577.73. The index gained some 655 points on earnings news and expectations from Chinese investors after the mainland government announced a pilot program that would allow Chinese citizens to invest in the Hong Kong stock market.

The speculative action caused most of the gains as many were trying to get in ahead of the influx of Chinese money. The action spread to the domestic market as many Chinese related names saw a huge increase in action. Some of the momentum names included: China Resources Development Inc. (CHNR), China Technology Development Group Corp (CTDC), eFuture Information Technology, Inc. (EFUT), Fuwei Films Holdings Limited (FFHL), China Grentech Corp Ltd. (GRRF), and Home Inns & Hotels Management Inc. (HMIN) shares all saw increased buying on the international news.

One name had two catalysts causing the increase in buying. China Precision Steel, Inc. (CPSL) gained some 30% on 2.81M shares traded. The name not only benefited from the China related news but also the news regarding U.S. Steel Corp’s acquisition of Stelco for a 43% premium over Stelco’s Friday close.

The acquisition was noted as strengthening U.S. Steel’s position as a supplier of flat rolled steel products in the North American Market.

The number 2 steel producer, Nucor, also announced that it had completed the previously announced acquisition of Magnatrax for $280 million in cash. The deals come at a time when leveraged buyouts are becoming much more scarce compared to months before. Though the actions were noted as being strategic, it still leaves many to wonder the fate of CPSL and the reasoning behind its large move.

One answer could have come six weeks ago when U.S. Steel and Arcelor Mittal CEO’s made comments noting that they saw more consolidation in the industry with a specific focus on China.

CPSL, according to their latest 10-Q, had around $11.4 million in cash and equivalents, and only $4 million in long term debt. The Company’s cash from operating activities had decreased significantly though the revenues year over year had increased. The increase in inventory seems to have been the cause for the decreased operating cash which could signify a problem in sales, preparing for a busier season, or the warding off of a future acquisition.

In any event, the speculative nature of Monday’s trading has the attention of many. While the Company does have some $75 million in assets, it only trades at a market cap of $154.5 million which might make it a little cheap considering its trailing twelve month price to earnings ratio being in the 14’s.

But the Company is heavily involved in the China sector and has even less regulation being involved in the Hong Kong area. Following its reverse merger in late December of last year, shares spiked from the $6 range to over $16 in only a few days. While that valuation certainly wasn’t warranted at the time, the name could become something to follow over the coming days. Speculation is abound and investors would be wise to follow the Hang Seng to gauge the interest these names might see in the following trading day. Investors would be wise to watch.



Visit 1800blogger to see all of our industry leading blogs

Labels: , , , , , ,

Monday, August 27, 2007

Market Comments Submitted by Nick at Ambitions as a Stock Trader

Submitted by My Ambitions as a Trader and Investor

Laterally Trending Market...

The current market conditions that we have been experiencing are quite possibly the most difficult to trade in. Laterally (or sideways) trending markets do not provide rewarding opportunities for both longs or shorts. Instead, they are filled with traps that can easily drain ones account. Trying to predict what the market will do next is not a game that I would like to play. It is a losing game at best. But still, by examining the chart a few days ago, I posted that if the DJIA can break above or close onto or above 13,200 that it would head higher and that if it closed below that point, it would have headed lower. Well it did close above the 13,200 point and lo and behold, it jumped up quite considerably. In order for the DJIA to break out above its 50 day MA, the 13,200 point needs to act as support (much like a spring board). Again, violating the 13,200 point can send the market further down again to retest the lows. Unless we trade sideways the whole time, next week should be rather interesting as far as the future direction of the market is concerned.

My Ambitions as a Trader and Investor is not a registered investment advisor. Please read the complete Small Cap Stocks Blog Disclaimer

Visit 1800blogger to see all of our industry leading blogs

Labels: , ,

Market Scan for Small Cap Stocks on August 25, 2007

Submitted by Ducimus Plinius

Market Scan for small cap stocks
at the close of the markets on August 24, 2007


The table below identifies the stocks returned on my scan of the US markets for small capitalizations stocks likely to display the characteristics of stocks entering Phase II, as described by Stan Weinstein.


Click Image to Enlarge



Ducimus Pliniusis not a registered investment advisor. Please read the complete Small Cap Stocks Blog Disclaimer

Visit 1800blogger to see all of our industry leading blogs

Labels: , , , , , , , , , , , , , , ,

Knobias ClipReport (8-27-2007)

Submitted from Knobias ClipReport

Friday’s session was greeted with positive economic data in the better than expected jump in new home sales. Sales of new homes increased 2.8% in July to a seasonally adjusted annual rate of 870,000 as the inventory of homes for sale dropped for a fourth straight month estimated by the Commerce Department. The Commerce Department also reported that orders for U.S. made durable goods surged in July, jumping 5.9% on higher demand for airplanes, vehicles, computers, machinery, steel and most other kinds of long-lasting manufactured goods. The gain far out paced the expected 1.5% forecast. The culmination caused a triple digit gain on the Dow putting aside subprime fears for the time being.

Some names weren't included in the day’s gains. One name that didn’t see some of the appreciation was Cortex Pharmaceuticals (COR).

The Company’s shares lost some 27.6% on 2,900,000 shares traded. Earlier in the month the Company reported a net loss of $2,850,000, or $0.07 per share for the quarter ended June 30, 2007 compared with a net loss of $4,398,000, or $0.13 per share for the corresponding prior year period. Non cash stock-based compensation charges for the quarter ended June 30, 2007 and 2006 were approximately $416,000 and $582,000, respectively.

Results for the quarter reflected decreased operating expenses, mostly resulting from reduced contract research expenses for the AMPAKINE(R) CX717 due to the timing of additional toxicology studies performed in prior periods.

The Company also announced that during the quarter, they intended to file an Investigational New Drug Application for CX717 with the Division of Psychiatry Products of the FDA to allow Cortex to initiate a Phase IIb study with the compound as a treatment for Attention Deficit Hyperactivity Disorder. Prior to the FDA clinical hold on the compound, the Company announced positive statistical and clinical results with CX717 in a Phase IIa trial in adults with that indication.

Regarding their cash balances, the Company noted that they anticipated having enough cash to support their funding requirements into 2008. The expectation seemed to be a little off.

On Friday, the Company announced that it had obtained commitments from several institutional investors to purchase shares of its common stock and warrants to purchase common stock in a registered direct offering for an aggregate purchase price of approximately $14.2 million. Under the terms of the transaction, Cortex expected to sell an aggregate of approximately 7.075 million shares of its common stock and warrants to purchase approximately 2.83 million shares of common stock. The warrants have an exercise price of $2.64 per share. Proceeds were noted to be used to accelerate development of AMPAKINE technology, licensing activities, working capital, capital expenditures and other general corporate purposes.

The action caused shares to tumble to their closing price of $1.90 on extremely high volume as many in the market felt a distrust towards management following their comments in the earnings release and subsequent actions regarding their cash position. With any continuation of Friday’s sell off, next week could see shares test lows in the $1.05 range not seen since the early months of this year.


Visit 1800blogger to see all of our industry leading blogs

Labels: , ,

Friday, August 24, 2007

Knobias ClipReport (8-24-2007)

Submitted from Knobias ClipReport

The cost of food has risen dramatically as many are already aware. The cost of corn and other commodities used as feed or actual raw material to produce other products have risen causing the final products to gain in price to offset the cost of rising raw materials. Because of the government’s plans to increase the use of ethanol, the cost of corn could continue to rise in the long term, and adding to the inflationary problem, the Fed ignores food and energy prices when gauging these inflationary concerns.

With the rising food prices, investors might want to hedge the cost of food by adding agricultural, food, or commodity related names to their portfolio.

One name that might be considered a decent hedge against the rising costs is Inventure Group Inc. (SNAK). The Company is engaged in the development, marketing, and distribution of consumer products that are sold through grocery, retailers, mass merchandisers, convenience stores, and vending distributors.

The Company’s portfolio of names includes Boulder Canyon, Braids Pretzels, Tato Skins, Poore Brothers, Rader Farms, Bob’s Texas Style and TGI Friday’s.

With 7 brands and over 50 products, the Company’s sales for the second quarter of fiscal 2007 were $22.9 million, up 24% compared to $18.5 million in the second quarter of 2006. Net income was reported at $300 thousand, or 2c per share, compared to $500 thousand or 3c per share.

The revenue growth was noted as being caused by the acquisition of Rader Farms which accounted for $4.3 million of second quarter net revenue. Rader Farms is a processor and marketer of frozen blueberries, raspberries, berry blends and other fruit products located in the state of Washington.

The Rader Farm acquisition was noted as being accretive to the earnings but was offset by increased commodity costs of $750 thousand. The Company noted in the conference call that they tried to offset the increased commodity costs by increased cost cutting initiatives and strategic price hikes. While the commodity cost increase was noted as being an industry wide problem, the Company noted that they will attempt to further offset the commodity cost increases with further cost cutting and pricing action. The latter was expected to occur in the fourth quarter.

The pricing action is where the Company can recoup the margins lost to the increased costs and while other competitors have drastically raised prices, Inventure Group only strategically raised prices on certain products. With a small increase in price on all products, the name could easily recoup some of the margins.

An additional top line growth initiative was a new product developed in collaboration with a national fast food chain. A line of snack foods are being developed with Burger King and are expected to be released by the end of the year. This French fry snack, which was noted as being developed over the past year and half, was set to be released through their normal distribution channels and could significantly provide top line growth.

Also of note was Burger King’s initiative to offer the snack products in their 7300 stores domestically following a successful testing. While a Burger King French fry snack may not seem like a very desirable food product, many of the TGIF’s line of snacks do not sound appetizing but are in fact, very good performers in the Company’s product line.

The conference call also let many investors into the fact that the Company had experienced some international growth in Mexico, Canada, and the U.K. While the Company has a cash and receivables balance in the $12 million range, one might think another acquisition is possible, especially one to inhibit the international sales growth. The Company noted it was a possibility but declared a pay down of the debt acquired in the Radar Farms acquisition as the main use of cash over the coming months.

With growth initiatives from organic means, pricing initiatives, and the new Burger King line of products, the name is certainly one to follow over the coming months. Investors would be wise to watch.


Visit 1800blogger to see all of our industry leading blogs

Labels: , ,

Market Scan for Small Cap Stocks on August 23, 2007

Submitted by Ducimus Plinius

Market Scan for small cap stocks
at the close of the markets on August 23, 2007


The table below identifies the stocks returned on my scan of the US markets for small capitalizations stocks likely to display the characteristics of stocks entering Phase II, as described by Stan Weinstein.



Click Image to Enlarge



Ducimus Pliniusis not a registered investment advisor. Please read the complete Small Cap Stocks Blog Disclaimer

Visit 1800blogger to see all of our industry leading blogs

Labels: , , , , , , , , ,

Thursday, August 23, 2007

Knobias ClipReport (8-23-2007)

Submitted from Knobias ClipReport

The overall market experienced saw optimism as many predicted the rally was a pricing in of a rate cut by the Fed in September. Inflationary concerns seem to be at the back of market’s mind even though it was a primary concern of the Fed over the past few months. The culmination of a rate cut and increasing inflation could be something many long term investors should consider. Merger and acquisition activity also raised optimism as online brokers TD Ameritrade and E-Trade were reportedly in talks.

Continuing the theme from last week, small cap bios trading at near cash levels have finally seen attention from many traders. Renovis Inc. (RNVS), Telik Inc. (TELK), Idenix Pharmaceuticals Inc. (IDIX), and Hollis Eden Pharmaceuticals (HEPH) were all higher from their mention last Thursday. Threshold Pharmaceuticals (THLD) and Gene Logic Inc. (GLGC) were close to even, while Pharmacyclics, Inc. (PCYC) was down.

Another name popped on the screen during Wednesday’s session and also had a positive news announcement.

Nuvelo, Inc. (NUVO) is a biopharmaceutical company dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy.

The Company’s latest 10-Q showed a current asset balance of $139 million while their market cap was just a shade over $100 million. On Wednesday, the Company announced enrollment of the first patient in the SONOMA-3 (Speedy Opening of Non-functional and Occluded catheters with Mini-dose Alfimeprase-3) trial evaluating lead product candidate, alfimeprase, for the treatment of central venous catheter occlusion (CO).

This open-label, single-arm trial will evaluate the safety and efficacy of a single 10 milligram dose of alfimeprase with a concentration of 5 milligrams per milliliter in up to 100 patients with occluded central venous catheters.

Following the news, Brean Murray reinstated coverage of the name with a Hold which was at a Sell before the suspension of their coverage. Also of note was a Schedule 13G filing on August 13th which displayed a position acquired by three 3 arms of an investment firm. The culmination of the shares equaled 8.4 million shares or 15.75% of the outstanding.

Earlier in the month, The Company announced that it was reducing its workforce by approximately 30% and realigning its organization to focus on core development programs that it believes will produce nearest-term proof-of- concept data. The company plans to continue to pursue development of alfimeprase, NU206 and NU172 and has decided to suspend development of rNAPc2 in all indications including cancer and acute coronary syndromes (ACS).

As a result of the reduction in workforce, effective August 3, 2007, the company expects to have less than 80 employees, a reduction of 45 percent from year end 2006. Nuvelo expects this realignment of personnel and programs to result in reduced annual expenses of approximately $15 million from current levels.

While shares were down heavily following their somewhat misleading earnings number earlier in the month, Wednesday’s session saw the name come back into favor of traders, gaining some 16.5% on 2.7M shares traded. While charges and extraordinary expenses may result from the work force cut, the name could be positioned now to focus on key products and return value to holders. With valuations this low and candidates in the pipeline, investors would be wise to watch.


Visit 1800blogger to see all of our industry leading blogs

Labels: , ,

Stocks to Watch and Market Comments Submitted by Nick at Ambitions as a Stock Trader

Submitted by My Ambitions as a Trader and Investor

Several Things....
This week is a bit busy for me so do not be surprised if my posting is not as frequent as other weeks. There are several things to keep an eye on. If we close at the HOD today, the DJIA will be in good shape to head higher as we have faced some resistance at the 13,200 level. If it can't close above this level, we may head down a bit to retest the area between 12,800-13,000. The NADSAQ needs to close above 2,550 in order to continue its short-term uptrend. If it faces resistance at that level, it may retest the 2,500 level. Likewise, the S&P also needs to close at levels near the HOD (which is slightly above its 200 day MA). Otherwise, it may run into some trouble and take another nasty dip. The Russell 2000 Index needs some more work in order to reclaim its 200 day MA. If it faces resistance and can't climb above the 200 day MA, it may be a good idea to initiate a short-term short position
in it.

As far as stocks are concerned, there are many stocks that have found support and pivot points off of their 200 day MA.

Some interesting stocks that are heating up the charts...


SVT

PLX- Avoid this stock if you are afraid of heights. This is undoubtedly a momentum play and a potential future high, tight flag candidate.

SHEN

VSEC (comeback?)

ACP

CCOI

VMW- Expect the stock to pullback a bit as it has had a quick run-up

SLI

ARTW

CVGW


My Ambitions as a Trader and Investor is not a registered investment advisor. Please read the complete Small Cap Stocks Blog Disclaimer

Visit 1800blogger to see all of our industry leading blogs

Labels: , , , , , , , , , ,

Market Scan for Small Cap Stocks on August 22, 2007

Submitted by Ducimus Plinius

Market Scan for small cap stocks
at the close of the markets on August 22, 2007


The table below identifies the stocks returned on my scan of the US markets for small capitalizations stocks likely to display the characteristics of stocks entering Phase II, as described by Stan Weinstein.



Click Image to Enlarge



Ducimus Pliniusis not a registered investment advisor. Please read the complete Small Cap Stocks Blog Disclaimer

Visit 1800blogger to see all of our industry leading blogs

Labels: , , , , , , ,

Wednesday, August 22, 2007

Stocks to Watch Submitted by Nick at Ambitions as a Stock Trader

Submitted by My Ambitions as a Trader and Investor

Stocks to Keep an Eye On...
Here are several stocks that you should simply keep an eye on. Buy them up if you would like at your own risk. Remember to keep any new buys small. Technically, one should be patient and not risk cash on either the long or short side at the moment, but sometimes several bullish charts emerge when you least expect them...

Keep an eye on:

NUAN
VMW (recent IPO)
VII (already recommended)
MPWR ( already recommended)
CVGW (good add on point)
CCOI
WLDN
FOSL
SURW
KOP
PLX (very volatile...risky play)
ETC (bottoming out)
PEGA
ARTW (bouncing off of the 50 day MA)

My Ambitions as a Trader and Investor is not a registered investment advisor. Please read the complete Small Cap Stocks Blog Disclaimer

Visit 1800blogger to see all of our industry leading blogs

Labels: , , , , , , , , , , , , , , ,

Market Scan for Small Cap Stocks on August 21, 2007

Submitted by Ducimus Plinius

Market Scan for small cap stocks
at the close of the markets on August 21, 2007


The table below identifies the stocks returned on my scan of the US markets for small capitalizations stocks likely to display the characteristics of stocks entering Phase II, as described by Stan Weinstein.



Click Image to Enlarge



Ducimus Pliniusis not a registered investment advisor. Please read the complete Small Cap Stocks Blog Disclaimer

Visit 1800blogger to see all of our industry leading blogs

Labels: , , , , ,

Knobias ClipReport (8-22-2007)

Submitted from Knobias ClipReport

MediciNova, Inc. (MNOV) announced results from its Phase Ib clinical trial of MN-221 for the treatment of preterm labor. Target plasma concentrations were achieved with an intravenous priming followed by maintenance infusion dosing paradigm. No significant safety concerns with MN-221 were identified in this clinical trial. The primary objectives of this clinical trial were to determine the pharmacokinetics, safety and tolerability of this infusion regimen of MN-221 in pregnant women. The intravenous formulation of MN-221 is also appropriate for use in emergency facilities.

There are no FDA-approved and marketed treatments for preterm labor in the U.S. All medications in current use are being used “off-label." Brethine(R) and Bricanyl(R)(terbutaline) are FDA-approved for the treatment of asthma, but they are commonly used “off-label” to treat preterm labor.

Chief Scientific Officer of MediciNova, Kenneth W. Locke, Ph.D., told Knobias on Tuesday, "Because MN-221 is a much more selective beta2 adrenergic receptor agonist than terbutaline, We believe that it should produce fewer cardiovascular side effects (e.g., palpitations)."

"MN-221 is also currently in a Phase IIa clinical trial for status asthmaticus, an acute exacerbation of asthma that does not respond to standard treatments of bronchodilators and corticosteroids. We expect to announce results from this trial during the fourth quarter of this year."

The Company has a broad broad pipeline of therapeutic product candidates that address significant disease markets, including six compounds in clinical testing. In addition to MN-221, the Company's other lead commercial candidate is MN-166, currently in a Phase II clinical trial for multiple sclerosis. MN-166 is an oral therapy that showed both neuroprotective and anti-inflammatory benefits in the first year of the trial, signifying the potential to reduce relapses and to halt or slow disease progression. Results from the second year of this study are expected during the first half of 2008.

Dr. Locke explained, "We have a wholly-owned subsidiary in Japan to establish relationships with many mid-size Japanese pharmaceutical companies, through which MediciNova has licensed the rights to develop several current product candidates. Our unique relationships provide us with an untapped source of novel therapeutics."

As of June 30, 2007, MediciNova had $85.9 million in cash or equivalents and an accumulated deficit of $191.8 million.

CFO Shintaro Asako noted, "We believe that our current financial resources will be sufficient to fund anticipated operating requirements, including planned research and development programs, through December 31, 2008."

"Our current strategy is to focus investment on key assets, such as MN-221 and MN-166, in order to bring these assets substantially forward towards commercialization, while pursuing a variety of business development initiatives for other product candidates in the pipeline."

Dutton recently reiterated a Strong Speculative Buy for MNOV with an ambitious target price of $20 a share by year-end. Punk Ziegel initiated coverage of MNOV at Buy and a price target of $22. The analyst indicated that the Company is an attractive investment opportunity that has not been recognized by the investment community.

Visit 1800blogger to see all of our industry leading blogs

Labels: , ,

Tuesday, August 21, 2007

Stock Promotions (8-21-2007)

It's being reported on StockPromoters.com, the best site on the Internet for following all the details about stock promotions the following new pink sheet stock promotions:

OTC Picks has been compensated $8,500 to promote SPNG.OB

OTC Reporter has been compensated 18 million free trading shares to promote QMMC.OB

Shazam Stocks has been compensated 125,000 shares to promote PRMO.PK

Twin Trader has been compensated $2,500 to promote MGUY.OB

Lebed.biz has been compensated 1 million restricted shares and $50,000 cash for a one year investor relations contract to promote XDSL.OB


Visit 1800blogger to see all of our industry leading blogs

Labels: , , , , , ,

Market Scan for Small Cap Stocks on August 20, 2007

Submitted by Ducimus Plinius

Market Scan for small cap stocks
at the close of the markets on August 20, 2007


The table below identifies the stocks returned on my scan of the US markets for small capitalizations stocks likely to display the characteristics of stocks entering Phase II, as described by Stan Weinstein.



Click Image to Enlarge



Ducimus Pliniusis not a registered investment advisor. Please read the complete Small Cap Stocks Blog Disclaimer

Visit 1800blogger to see all of our industry leading blogs

Labels: , , , , , ,

Knobias ClipReport (8-21-2007)

Submitted from Knobias ClipReport

BioLife Solutions Inc. (BLFS) has signed an agreement as the exclusive supplier of preservation media to the New England Cryogenic Center, Inc. (NECC), a global provider of cryogenically preserved human cells and tissues. The five year agreement includes volume based pricing and an exclusive commitment from NECC to purchase all of its demand for cord blood preservation media from BioLife.

CEO Michael Rice told Knobias on Monday, "We are not able to disclose the financial terms of this agreement. This is a competitive market and pricing and other terms are confidential between BioLife and our respective customers. We anticipate incremental revenue generation from this agreement starting in Q4."

BioLife Solutions develops, manufactures and markets patented hypothermic storage and cryopreservation solutions for cells, tissues, and organs. The Company's proprietary HypoThermosol(R) and CryoStor(TM) platform of solutions are marketed to academic and commercial organizations worldwide that areinvolved in cell therapy, tissue engineering, cord blood banking, drug discovery, and toxicology testing. BioLife's products are serum-free and protein-free, fully defined, and are formulated to reduce or prevent preservation-induced, delayed-onset cell damage and death.

The HypoThermosol line of preservation solutions is designed to prepare and preserve cells, tissues and organs for low temperature (2-10 degrees celsius) environments and short-term cold storage or transportation. CryoStor provides a safe, protective environment for cells and tissues during the freezing, storage, and thawing process. Through modulating the cellular biochemical response to the cryopreservation process, CryoStor provides for enhanced cell viability and functionality while eliminating the need to include serum, proteins or high levels of cytotoxic agents.

Mr. Rice explained, "Our technology is vastly different from traditional preservation media in that the formulations are based on a detailed understanding of the cellular molecular response to cold temperatures. Our scientists identified the specific pathways that cause cells to initiate pre-programmed death in response to stress (cold), and also the mechanisms by which water flows into and out of the cells during the freezing and thawing processes. From these discoveries, the optimal formulations were designed to reduce or prevent preservation induced injuries to the cells."

"The main competitive product is one a few variants of a home-brewed formulation of preservation media that includes DMSO (the anti-freeze component) along with culture media, serum, or some starch component. Invitrogen (IVGN) and Lonza are two life sciences companies that offer preservation media products."

"Some of our major customers include Centocor, Bioheart, Intercytex and several other cell therapy customers."

"BioLife also offers research for customers to determine the optimal variant of HypoThermosol or CryoStor that will provide the best post-preservation results for the specific cell or tissue type the customer is working with."

Product sales for the quarter ended June 30, 2007 increased to $201,850, compared to $156,318 for the quarter ended June 30, 2006. Net loss per share was $0.01 versus a loss per share of $0.01 for the same period in 2006.The Company has cash and cash equivalents of $707,074 and an accumulated deficit of $43 million.

In February 2007, the Company borrowed $750,000, represented by two promissory note agreements from two stockholders. The Company also borrowed $1 million from two stockholders in June 2007.

He concluded, "We are too early in our commercialization plan to provide guidance, but BioLife is very strongly positioned to capitalize on the growth potential in the cord blood and stem cell markets. A growing list of marquee customers have selected our products because we offer the best post-preservation cell and tissue yield and function. This is critically important for every clinical company, since therapeutic dosages and patient outcomes are dependent on the robustness and quality of the preservation process."



Visit 1800blogger to see all of our industry leading blogs

Labels: , , ,

Monday, August 20, 2007

Stock Picks Submitted by Nick at Ambitions as a Stock Trader

Submitted by My Ambitions as a Trader and Investor

Several Bullish Charts Emerge...



Despite the markets current indecisive nature, the last few days bounce has helped a few charts create bullish technical setups on their charts. I am not recommending them as buys just yet. I would like to see how the week starts off and how these stocks react. If they continue to look bullish it may be alright to buy just a little at first. Right now is not exactly the time to create big positions. All it takes is one negative news release to send us below the 200 day MA once again.

TRAK


ISRG


LKQX



MEAS


RBN


QEPC


RGEN


UA


STRL


STRA


NUAN


My Ambitions as a Trader and Investor is not a registered investment advisor. Please read the complete Small Cap Stocks Blog Disclaimer

Visit 1800blogger to see all of our industry leading blogs

Labels: ,

Market Scan for Small Cap Stocks on August 17, 2007

Submitted by Ducimus Plinius

Market Scan for small cap stocks
at the close of the markets on August 17, 2007


The table below identifies the stocks returned on my scan of the US markets for small capitalizations stocks likely to display the characteristics of stocks entering Phase II, as described by Stan Weinstein.



Click Image to Enlarge



Ducimus Pliniusis not a registered investment advisor. Please read the complete Small Cap Stocks Blog Disclaimer

Visit 1800blogger to see all of our industry leading blogs

Labels: , , , ,